



Curriculum Vitae Europass

PERSONAL INFORMATION

Name / Surname **Gianni BINOTTO**

Address Padua School of Medicine- Dept of Medicine, Hematology and Clinical Immunology
Via Giustiniani 2 – 35128 PADOVA- Italy

Phone +39 (049) 8217096

Fax +39 (049) 8218934

E-mail gianni.binotto@unipd.it

Nationality italian

Date of birth 20/09/1973

Sex male

JOB POSITION **Hospital Assistant Medical Director, Hematology and Clinical Immunology Unit,
Azienda Ospedaliera/ Padua University Medical School, Padua**

WORK EXPERIENCE

- 2008 to date, Hospital Assistant Medical Director, Hematology and Clinical Immunology Unit, Azienda Ospedaliera, Padua.
- 2004 to 2008, member of clinical equipe of the Hematology and Clinical Immunology Branch, Department of Clinical & Experimental Medicine, Padua University Medical School.
- 2004 to 2008, research grant holder, Padua University.

EDUCATION AND TRAINING

- 1999, Medical Doctor, Padua University School of Medicine
- 2003, Board in Hematology, Padua University School of Medicine

ADDITIONAL INFORMATION

Activities pertinent to professional qualification

Management of autologous bone marrow transplantation procedures.

Morphological evaluation of bone marrow and peripheral blood smears.

Clinical management of chronic myeloid leukemia and myelodysplastic syndromes.

Involved as study coordinator, investigator and data manager in several phase II and III clinical trials concerning myeloproliferative, myelodysplastic and lymphoproliferative disorders.

Knowledge of ICH-GCP guidelines.

Member of pain and clinical risk management program committees.

Involved in scientific educational activities on behalf of LABNET Educational Board.

Member of JAKNET Educational Board.

Research interests

From 1999, engaged in research studies about pathogenesis of chronic lymphoproliferative disorders, role of chemokines in compartmentalization of normal and neoplastic lymphocytes and immunological reconstitution after allogeneic bone marrow transplantation.

Publications and invited lectures

Author and co-author of 30 scientific papers, several abstracts presented at international meetings; co-author of oncohematologic books.

Invited lecturer at several national and international meetings concerning chronic myeloid leukemia and myelodysplastic syndromes.

Teaching activity

Post-graduate school:

Post-graduate school of Hematology, Padua University Medical School

Post-graduate school of Oncology, Padua University Medical School

Nurses:

Antiblastic drugs management training.

Teaching session on morphological evaluation of bone marrow and peripheral blood smears.

Research awards

2006, winner of "Cecilia per la ricerca" award with the research project: "Role of mitochondrial DNA in pathogenesis of multiple myeloma".

Scientific societies

Member of the Italian Society of Hematology (SIE).

Member of the European Hematology Association (EHA).

Publications

1. Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
Haematologica. 2016;101:1200-1207.
2. Quotti Tubi L, Canovas Nunes S, Brancalion A, Doriguzzi Breatta E, Manni S, Mandato E, Zaffino F, Macaccaro P, Carrino M, Gianesin K, Trentin L, Binotto G, Zambello R, Semenzato G, Gurrieri C, Piazza F. Protein kinase CK2 regulates AKT, NF- κ B and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
Leukemia. 2016 [Epub ahead of print].
3. Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Oncotarget. 2016 [Epub ahead of print].
4. Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Leuk Res. 2015;39:1055-9.
5. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Leukemia. 2015;29:1823-31.
6. Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, Tiribelli M; Gruppo Triveneto LMC.. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Haematologica. 2015;100:e299-301.

7. Tiribelli M, Binotto G, Calistri E, Maino E, Scaffidi L, Medeot M, Nabergoj M, Ambrosetti A, Semenzato G, Fanin R, Bonifacio M; Gruppo Triveneto LMC. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Am J Hematol. 2015;90:E135-7.
8. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party.. Differences among young adults, adults and elderly chronic myeloid leukemia patients.
Ann Oncol. 2015;26:185-92.
9. Breccia M, Binotto G. Bosutinib for Chronic Myeloid Leukemia.
Rare Cancers Ther. 2015;3:35-46.
10. Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Specchia G, Rosti G, Alimena G. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Leuk Res. 2014;38:1173-6.
11. Lessi F, Binotto G, Castelli M, Colpo A, Rolma G, Vianello F. Non-hepatosplenic extramedullary haematopoiesis in primary myelofibrosis.
Br J Haematol. 2014;165:271.
12. Bonifacio M, Binotto G, Calistri E, Maino E, Tiribelli M; Gruppo Triveneto LMC. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Ann Hematol. 2014;93:163-4.
13. Briani C, Dalla Torre C, Citton V, Manara R, Pompanin S, Binotto G, Adami F. Cobalamin deficiency: clinical picture and radiological findings.
Nutrients. 2013;5:4521-39.
14. Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, Fanin R. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Leuk Res.;37:1457-60.
15. Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
Blood. 2013;122:1634-48.

16. Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Drugs Aging. 2013;30:629-37.
17. Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. Quality of life and physicians' perception in myelodysplastic syndromes.
Am J Blood Res. 2012;2:136-47.
18. Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Leuk Res. 2011;35:1164-9.
19. Adami F, Scarin M, Pescarini L, Binotto G, Pavan L, Sgarabotto D, Semenzato G. Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B.
Mycoses. 2011;54:365-9.
20. Binotto G, Cillo U, Trentin L, Piazza F, Zaninotto M, Semenzato G, Adami F. Double autologous bone marrow transplantation and orthotopic liver transplantation in a patient with primary light chain (AL) amyloidosis.
Amyloid 2011;18 Suppl 1:132-4.
21. Fadini GP, Albiero M, Menegazzo L, Boscaro E, Vigili de Kreutzenberg S, Agostini C, Cabrelle A, Binotto G, Rattazzi M, Bertacco E, Bertorelle R, Biasini L, Mion M, Plebani M, Ceolotto G, Angelini A, Castellani C, Menegolo M, Grego F, Dimmeler S, Seeger F, Zeiher A, Tiengo A, Avogaro A. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes.
Circ Res. 2011;108:1112-21.
22. Adami F, Briani C, Binotto G, Altinier S, Tarantini G, Semenzato G. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
Am J Hematol. 2010;85:131-2.
23. Piva E, Pajola R, Binotto G, Plebani M. Jordans' anomaly in a new neutral lipid storage disease.
Am J Hematol. 2009;84:254-5.

24. Cabrelle A, Maschio N, Carraro S, Frezzato F, Binotto G, Gattazzo C, Miorin M, Agostini C, Zambello R, Pandolfi F, Semenzato G, Trentin L. Apoptotic effect of cyclosporin a and dexamethasone in malignant cells of patients with B-chronic lymphocytic leukemia.
J Biol Regul Homeost Agents. 2009;23:239-50.
25. Trentin L, Miorin M, Facco M, Baesso I, Carraro S, Cabrelle A, Maschio N, Bortoli M, Binotto G, Piazza F, Adami F, Zambello R, Agostini C, Semenzato G. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.
Br J Haematol. 2007;138:594-602.
26. Zambello R, Berno T, Cannas G, Baesso I, Binotto G, Bonoldi E, Bevilacqua P, Miorin M, Facco M, Trentin L, Agostini C, Semenzato G. Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL).
Blood. 2005;106:3926-31.
27. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R, Adami F, Agostini C, Semenzato G. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas.
Blood. 2004;104:502-8.
28. Binotto G, Trentin L, Semenzato G. Ifosfamide and cyclophosphamide: effects on immunosurveillance.
Oncology. 2003;65 Suppl 2:17-20.
29. Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, Semenzato G. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection.
Am J Pathol. 2001;158:1703-11.
30. Agostini C, Siviero M, Facco M, Carollo D, Binotto G, Tosoni A, Cattelan AM, Zambello R, Trentin L, Semenzato G. Antiapoptotic effects of IL-15 on pulmonary Tc1 cells of patients with human immunodeficiency virus infection.
Am J Respir Crit Care Med. 2001;163:484-9.

Mother tongue **Italian**

Other languages

English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Listening	
C1	C2	C1	C1	C1

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Sign



15th November 2016